Clinical Trial Update: NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of NovoTTF-200A in combination with pembrolizumab for metastatic melanoma with brain metastases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Melanoma Brain Metastasis

Drugs mentioned

• NOVOTTF-200A
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Brown University | Conditions: Metastatic Melanoma, Melanoma Brain Metastasis | Phase 1, Phase 2 | Status: WITHDRAWN